Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 2/20 | 0.32 |
| ▸ | EDNRB | P24530 | 1/20 | 0.32 |
| ▸ | EDNRA | P25101 | 1/20 | 0.32 |
| ▸ | S100A4 | P26447 | 3/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | APAF1 | O14727 | 1/20 | 0.31 |
| ▸ | TERT | O14746 | 1/20 | 0.31 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.31 |
| ▸ | TDP2 | O95551 | 1/20 | 0.31 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11411069 | 0.76 | POLB (0.40) | MEN1KMT2APOLBALDH1A1ALOX15 | |
| SCHEMBL11052520 | 0.76 | POLB (0.40) | MEN1KMT2APOLBALDH1A1ALOX15 | |
| SCHEMBL6314591 | 0.76 | MEN1 (0.40) | MEN1KMT2APOLBALDH1A1ALOX15 | |
| SCHEMBL1032657 | 0.76 | KMT2A (0.40) | MEN1KMT2APOLBALDH1A1ALOX15 | |
| SCHEMBL9617399 | 0.76 | MEN1 (0.40) | MEN1KMT2APOLBALDH1A1ALOX15 | |
| SCHEMBL8011185 | 0.73 | ALDH1A1 (0.46) | MEN1KMT2APOLBALDH1A1MAPK1 | |
| SCHEMBL10670754 | 0.73 | MEN1 (0.38) | MEN1KMT2APOLBALDH1A1ALOX15 | |
| SCHEMBL11416663 | 0.72 | MEN1 (0.36) | MEN1KMT2APOLBALDH1A1ALOX15 | |
| SCHEMBL21533082 | 0.72 | MEN1 (0.36) | MEN1KMT2APOLBALDH1A1ALOX15 | |
| SCHEMBL10512037 | 0.72 | POLB (0.36) | MEN1KMT2APOLBALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327375-A1 | SUBSTITUTED HETEROBICYCLIC DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTOR | ADDEX PHARMA S.A. (CH) | 2024-10-03 | — | — | US | disclosed |
| EP-4337643-A1 | SUBSTITUTED HETEROBICYCLIC DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTOR | Addex Pharma S.A (CH) | 2024-03-20 | — | — | EP | disclosed |
| CN-117597331-A | Substituted heterobicyclic derivatives as MGLU7 receptor negative allosteric modulators | 阿德克斯法尔马股份公司 | 2024-02-23 | — | — | CN | disclosed |
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-05 | — | — | US | disclosed |
| EP-4161905-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | Arbutus Biopharma Corporation (CA) | 2023-04-12 | — | — | EP | disclosed |
| CN-108250150-B | Peptide ketone compound and preparation method and application thereof | 兰州大学 | 2020-12-29 | — | — | CN | disclosed |
| EP-3275870-B1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-3275870-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | Gilead Sciences, Inc. (US) | 2018-01-31 | — | — | EP | disclosed |
| EP-2707361-B1 | FUSED HETEROCYCLIC COMPOUNDS AS SODIUM CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2017-08-23 | — | — | EP | disclosed |
| US-9682998-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| WO-2007107469-A1 | METHODS OF INHIBITING BTK AND SYK PROTEIN KINASES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-09-27 | — | — | WO | disclosed |
| US-20070219195-A1 | e.g. 4-(5-Methyl-2H-pyrazole-3-ylamino)-phenyl-2H-phthalazin-1-one2-Phenyl-2,3-dihydro-phthalazine-1,4-dione; tyrosine kinase inhibitor; antiinflammatory agent; asthma, rheumatoid arthritis, systemic lupus erythematosus or multiple sclerosis | ROCHE PALO ALTO LLC | 2007-09-20 | — | — | US | disclosed |
| EP-1794148-A1 | NOVEL PHTHALAZINONE DERIVATIVES, AS AURORA-A KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-06-13 | — | — | EP | disclosed |
| US-7226923-B2 | Phthalazinone derivatives | HOFFMAN-LA ROCHE INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-20060089359-A1 | Phthalazinone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-27 | — | — | US | disclosed |
| WO-2006032518-A1 | NOVEL PHTHALAZINONE DERIVATIVES, AS AURORA-A KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-30 | — | — | WO | disclosed |
| US-20050256124-A1 | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-11-17 | — | — | US | disclosed |
| WO-2005103039-A1 | 2- (3-AMINOPYRROLIDIN-1-YL) PYRIDINES AS MELANIN-CONCENTRATING HORMONE RECEPTOR AN TAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| US-4898872-A | Imidazo[4,5-b]pyridyl quinolone cardiac stimulants | PFIZER INC. (US) | 1990-02-06 | — | — | US | disclosed |
| EP-0290153-A1 | Heterobicyclic quinolone derivatives | Pfizer Limited (GB) | 1988-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089359-A1 | Phthalazinone derivatives | SDHA, SDHB, CYP3A5 | MEN1 657/4885KMT2A 2955/4885POLB 819/4885 |
| US-20070219195-A1 | e.g. 4-(5-Methyl-2H-pyrazole-3-ylamino)-phenyl-2H-phthalazin-1-one2-Phenyl-2,3-dihydro-phthalazine-1,4-dione; tyrosine kinase inhibitor; antiinflammatory agent; asthma, rheumatoid arthritis, systemic lupus erythematosus or multiple sclerosis | SYK, BTK, LCK | MEN1 3550/4885KMT2A 410/4885POLB 2152/4885 |
| US-20240327375-A1 | SUBSTITUTED HETEROBICYCLIC DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTOR | GRM7, GRM2, GRM1 | MEN1 3113/4885KMT2A 1571/4885POLB 2865/4885 |
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | NSD3, PML, NSD1 | MEN1 2151/4885KMT2A 201/4885POLB 1369/4885 |
| US-20050256124-A1 | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto | MCHR1, MCHR2, MC1R | MEN1 1006/4885KMT2A 1469/4885POLB 4389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.